Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Alteration of Ppar-Gamma (Pparg; Pparγ) and Pten Gene Expression in Acute Myeloid Leukemia Patients and the Promising Anticancer Effects of Pparγ Stimulation Using Pioglitazone on Aml Cells Publisher Pubmed



Esmaeili S1 ; Salari S2 ; Kaveh V3 ; Ghaffari SH4 ; Bashash D1
Authors
Show Affiliations
Authors Affiliations
  1. 1. Department of Hematology and Blood Banking, School of Allied Medical Sciences, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  2. 2. Department of Medical Oncology, Hematology and Bone Marrow Transplantation, Taleghani Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran
  3. 3. Department of Medical Oncology and Hematology, Iran University of Medical Sciences, Tehran, Iran
  4. 4. Hematology, Oncology and Stem Cell Transplantation Research Center, Shariati Hospital, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran

Source: Molecular Genetics and Genomic Medicine Published:2021


Abstract

Background: In the new era of tailored cancer treatment strategies, finding a molecule to regulate a wide range of intracellular functions is valuable. The unique property of nuclear receptor peroxisome proliferator-activated receptor-γ (PPARγ; PPARG) in transmitting the anti-survival signals of the chemotherapeutic drugs has fired the enthusiasm into the application of this receptor in cancer treatment. Objectives: We aimed to investigate the expression of PPARγ and one of its downstream targets PTEN in non-M3 acute myeloid leukemia (AML) patients. We also investigated the therapeutic value of PPARγ stimulation using pioglitazone in the AML-derived U937 cell line. Methods: The blood samples from 30 patients diagnosed with non-M3 AML as well as 10 healthy individuals were collected and the mRNA expression levels of PPARγ and PTEN were evaluated. Additionally, we used trypan blue assay, MTT assay, and flow cytometry analysis to evaluate the anti-leukemic effects of pioglitazone on U937 cells. Results: While PTEN was significantly downregulated in AML patients as compared to the control group, the expression of PPARγ was increased in the patients’ group. The expression level of PPARγ was also negatively correlated with PTEN; however, it was not statistically significant. Besides, PPARγ stimulation using pioglitazone reduced survival and proliferative capacity of U937 cells through inducing apoptosis and suppression of cell transition from the G1 phase of the cell cycle. Conclusion: The results of the present study shed more light on the importance of PPARγ and its stimulation in the therapeutic strategies of AML. © 2021 The Authors. Molecular Genetics & Genomic Medicine published by Wiley Periodicals LLC.